Excelsior Biopharma Inc. (TPEX:6496)
Taiwan · Delayed Price · Currency is TWD 24.65
+0.20 (0.82%)
Sep 7, 2026, 2:31 PM CST
Excelsior Biopharma Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,148 | 1,367 | 1,406 | 1,356 | 1,298 | 1,363 | |
Market Cap Growth | -17.85% | -2.78% | 3.69% | 4.50% | -4.79% | -1.48% |
Enterprise Value | 1,532 | 1,666 | 1,504 | 756 | 549 | 605 |
Last Close Price | 24.65 | 29.25 | 29.95 | 28.85 | 27.80 | 29.25 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Forward PE | - | 10.56 | 10.56 | 10.56 | 10.56 | 10.56 |
PS Ratio | 1.23 | 1.52 | 1.63 | 1.76 | 1.93 | 1.02 |
PB Ratio | 1.67 | 1.70 | 1.42 | 1.23 | 1.08 | 1.11 |
P/TBV Ratio | 1.67 | 1.70 | 1.42 | 1.23 | 1.08 | 1.11 |
P/FCF Ratio | - | - | - | - | - | 25.75 |
P/OCF Ratio | - | - | - | - | 236.59 | 24.42 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.64 | 1.86 | 1.75 | 0.98 | 0.82 | 0.45 |
EV/EBITDA Ratio | - | - | - | - | - | 94.72 |
EV/FCF Ratio | - | - | - | - | - | 11.43 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.76 | 0.64 | 0.41 | 0.32 | 0.29 | 0.30 |
Debt / EBITDA Ratio | - | - | - | - | - | 18.34 |
Debt / FCF Ratio | - | - | - | - | - | 6.89 |
Net Debt / Equity Ratio | 0.56 | 0.41 | 0.16 | -0.21 | -0.62 | -0.60 |
Net Debt / EBITDA Ratio | -2.11 | -2.14 | -2.42 | 3.40 | 46.03 | -115.59 |
Net Debt / FCF Ratio | -2.36 | -1.86 | -0.45 | 1.38 | 328.79 | -13.94 |
Asset Turnover | 0.66 | 0.59 | 0.55 | 0.47 | 0.38 | 0.72 |
Inventory Turnover | 1.85 | 1.83 | 1.85 | 2.29 | 1.96 | 4.35 |
Quick Ratio | 0.75 | 1.13 | 1.95 | 4.53 | 2.71 | 5.26 |
Current Ratio | 1.55 | 1.95 | 3.43 | 5.92 | 3.15 | 6.12 |
Return on Equity (ROE) | -26.05% | -20.40% | -9.42% | -7.87% | -2.77% | -1.24% |
Return on Assets (ROA) | -8.80% | -7.00% | -3.21% | -3.08% | -1.03% | -0.29% |
Return on Invested Capital (ROIC) | -18.26% | -15.05% | -8.02% | -12.28% | -6.20% | -1.76% |
Return on Capital Employed (ROCE) | -20.60% | -15.40% | -6.00% | -5.70% | -2.30% | -0.60% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -17.99% | -13.40% | -7.02% | -6.71% | -2.60% | -1.15% |
FCF Yield | -14.14% | -12.85% | -25.38% | -12.56% | -0.18% | 3.88% |
Buyback Yield / Dilution | -0.40% | -0.12% | -0.42% | -0.15% | 1.42% | 5.56% |
Total Shareholder Return | -0.40% | -0.12% | -0.42% | -0.15% | 1.42% | 5.56% |